Get started
Gilead Sciences, Inc.Gilead Sciences, Inc.Gilead Sciences, Inc.

Gilead Sciences, Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


Gilead’s option rights to certain Arcus early-stage programs will expire in July after Gilead didn’t pay the continuation fee; Gilead keeps existing time-limited options, no new option rights.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪170.84 B‬ USD
Dividend yield (indicated)
2.38%
Price to earnings Ratio (TTM)
20.43
Basic EPS (TTM)
6.84 USD
Net income (FY)
‪8.51 B‬ USD
Revenue (FY)
‪29.45 B‬ USD
Shares float
‪1.24 B‬
Beta (1Y)
0.30

Employees


Employees (FY)
‪17 K‬
Change (1Y)
−600 −3.41%
Revenue / Employee (1Y)
‪1.73 M‬ USD
Net income / Employee (1Y)
‪500.59 K‬ USD

About Gilead Sciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel P. O'Day
Website
gilead.com
Headquarters
Foster City
Founded
1987
IPO date
Jan 22, 1992
Identifiers
3
ISIN US3755581036
CFI code
ESVUFR
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Check out other big names from the same industry as GILD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


5.711% YTM
Maturity date Nov 15, 2064
Coupon 5.60% (Fixed)
5.648% YTM
Maturity date Oct 15, 2053
Coupon 5.55% (Fixed)
5.638% YTM
Maturity date Nov 15, 2054
Coupon 5.50% (Fixed)
5.587% YTM
Maturity date Oct 1, 2050
Coupon 2.80% (Fixed)
5.582% YTM
Maturity date Mar 1, 2047
Coupon 4.15% (Fixed)
5.574% YTM
Maturity date Mar 1, 2046
Coupon 4.75% (Fixed)
5.543% YTM
Maturity date Feb 1, 2045
Coupon 4.50% (Fixed)
5.527% YTM
Maturity date Apr 1, 2044
Coupon 4.80% (Fixed)
5.359% YTM
Maturity date Dec 1, 2041
Coupon 5.65% (Fixed)
5.238% YTM
Maturity date Oct 1, 2040
Coupon 2.60% (Fixed)
4.850% YTM
Maturity date Sep 1, 2036
Coupon 4.00% (Fixed)

See all GILD bonds 

ETFs holding the stock


VTI
Vanguard Total Stock Market ETF
Weight 0.27%
Market value ‪5.50 B‬
VOO
Vanguard S&P 500 ETF
Weight 0.31%
Market value ‪4.40 B‬
QQQ
Invesco QQQ Trust, Series 1
Weight 0.85%
Market value ‪3.59 B‬
IVV
iShares Core S&P 500 ETF
Weight 0.28%
Market value ‪2.16 B‬
SPY
SPDR S&P 500 ETF TRUST
Weight 0.28%
Market value ‪2.00 B‬
VTV
Vanguard Value ETF
Weight 0.71%
Market value ‪1.60 B‬
XLV
State Street Health Care Select Sector SPDR ETF
Weight 3.18%
Market value ‪1.23 B‬
VIG
Vanguard Div Appreciation ETF
Weight 0.82%
Market value ‪968.16 M‬
VYM
Vanguard High Dividend Yield ETF
Weight 0.76%
Market value ‪679.58 M‬
QQQM
Invesco NASDAQ 100 ETF
Weight 0.85%
Market value ‪671.49 M‬
IBB
iShares Biotechnology ETF
Weight 7.26%
Market value ‪615.46 M‬

Explore more ETFs 

Frequently asked questions


The current price of GILD is 135.87 USD — it has decreased by −0.09% in the past 24 hours. Watch Gilead Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gilead Sciences, Inc. stocks are traded under the ticker GILD.
GILD stock has fallen by −0.35% compared to the previous week, the month change is a −2.08% fall, over the last year Gilead Sciences, Inc. has showed a 29.72% increase.
We've gathered analysts' opinions on Gilead Sciences, Inc. future price: according to them, GILD price has a max estimate of 180.00 USD and a min estimate of 123.00 USD. Watch GILD chart and read a more detailed Gilead Sciences, Inc. stock forecast: see what analysts think of Gilead Sciences, Inc. and suggest that you do with its stocks.
GILD reached its all-time high on Feb 11, 2026 with the price of 157.29 USD, and its all-time low was 0.21 USD and was reached on Jun 8, 1994. View more price dynamics on GILD chart.
See other stocks reaching their highest and lowest prices.
GILD stock is 2.26% volatile and has beta coefficient of 0.30. Track Gilead Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gilead Sciences, Inc. there?
Today Gilead Sciences, Inc. has the market capitalization of ‪168.64 B‬, it has decreased by −1.00% over the last week.
Yes, you can track Gilead Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Gilead Sciences, Inc. is going to release the next earnings report on Apr 23, 2026. Keep track of upcoming events with our Earnings Calendar.
GILD earnings for the last quarter are 1.86 USD per share, whereas the estimation was 1.81 USD resulting in a 2.76% surprise. The estimated earnings for the next quarter are 1.91 USD per share. See more details about Gilead Sciences, Inc. earnings.
Gilead Sciences, Inc. revenue for the last quarter amounts to ‪7.92 B‬ USD, despite the estimated figure of ‪7.69 B‬ USD. In the next quarter, revenue is expected to reach ‪6.91 B‬ USD.
GILD net income for the last quarter is ‪2.18 B‬ USD, while the quarter before that showed ‪3.05 B‬ USD of net income which accounts for 0.00% change. Track more Gilead Sciences, Inc. financial stats to get the full picture.
Yes, GILD dividends are paid quarterly. The last dividend per share was 0.82 USD. As of today, Dividend Yield (TTM)% is 2.35%. Tracking Gilead Sciences, Inc. dividends might help you take more informed decisions.
Gilead Sciences, Inc. dividend yield was 2.57% in 2025, and payout ratio reached 46.60%. The year before the numbers were 3.33% and 805.23% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 21, 2026, the company has ‪17 K‬ employees. See our rating of the largest employees — is Gilead Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Gilead Sciences, Inc. EBITDA is ‪14.56 B‬ USD, and current EBITDA margin is 49.52%. See more stats in Gilead Sciences, Inc. financial statements.
Like other stocks, GILD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gilead Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gilead Sciences, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gilead Sciences, Inc. stock shows the buy signal. See more of Gilead Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.